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Why Do Some Lung Cancer Patients Receive No
Anticancer Treatment?
Shalini K. Vinod, MD,*† Mark A. Sidhom, MBBS,* Gabriel S. Gabriel, FAFPHM,†
Mark T. Lee, MBBS,* and Geoff P. Delaney, PhD*
Introduction: A significant proportion of lung cancer patients
receive no anticancer treatment. This varies from 19% in USA, 33%
in Australia, 37% in Scotland, and 50% in Ireland. The aim of this
study was to identify the reasons behind this.
Methods: The Lung Cancer Multidisciplinary Meeting (MDM) in
South-West Sydney prospectively collects data on all patients
presented. All new lung cancer patients presented between De-
cember 1, 2005, and December 31, 2007, were reviewed. Patients
were assigned optimal treatment based on evidence-based guide-
lines. Those patients in whom guidelines recommended no treat-
ment (GNT) were compared with those whom the MDM recom-
mended no treatment (MNT) and with those who actually
received no treatment (ANT).
Results: There were 335 patients with a median age of 69 years.
A total of 82% had non-small cell lung cancer, 14% had small
cell lung cancer, and 4% had no pathologic diagnosis. Eighty-five
percent had locally advanced or metastatic disease. GNT was
recommended in 4% (n  13), MNT in 10% (n  32) but ANT
comprised 20% (n  66). The differences between GNT and
MNT were mainly due to patient comorbidities and clinician
decision, but the differences between MNT and ANT were due to
patient preference and declining performance status. In multivar-
iate analysis, older age, poorer Eastern Cooperative Oncology
Group status, non-small cell lung cancer, and non-English lan-
guage predicted for ANT.
Conclusions: The proportion of patients with lung cancer receiving
no treatment is greater than that predicted by guidelines or recom-
mended by the MDM but lower than that described in population-
based studies suggesting that MDMs can improve treatment utiliza-
tion in lung cancer.
Key Words: Lung neoplasms, Treatment utilization, Radiotherapy,
Chemotherapy, Patterns of care.
(J Thorac Oncol. 2010;5: 1025–1032)
Lung cancer is the leading cause of cancer related mortalityin most Western nations.1–4 The 5-year survival is poor in
the order of 10 to 15%. This can only be improved through
the use of anticancer therapies namely surgery, radiotherapy,
and chemotherapy including biologic agents. Survival is
consistently better in patients who receive anticancer treat-
ment compared with those who do not.5 At the population
level, survival is improved in populations that have higher
rates of active treatment.6
However, there is worldwide variation in treatment
utilization for lung cancer.5,7–10 Lung cancer patients in
USA are the most likely to receive treatment, with a
treatment utilization rate of 81%.5 In contrast, only 50% of
lung cancer patients in Ireland and New Zealand, 63% in
Scotland, and 67% in Australia receive anticancer treat-
ment.7,9,11,12 In a disease with increasing incidence and
poor survival, and where screening has not been shown to
reduce mortality, outcomes can only be improved with the
delivery of anticancer treatment.
Lung cancer studies have identified that not all pa-
tients who might warrant treatment actually receive treat-
ment.7,9,12,13 Why then are a significant number of patients
not receiving any treatment? Lung cancer is primarily a
cancer of the elderly with median age close to 70
years.7,11,12 Older patients are at higher risk of suffering
complications from surgery and are poorly represented in
trials of chemotherapy and radiotherapy.14 In addition,
coexisting comorbidities can limit the ability to treat pa-
tients optimally. The incidence of comorbidity increases
with age and is double for lung cancer patients than that of
the general population.15,16 Temporal trends in the Amer-
ican lung cancer population have shown that this popula-
tion is getting older with a greater number of comorbidi-
ties.17
Although there are many valid reasons where anti-
cancer treatment may not be appropriate, there are other
factors that have been associated with lack of treatment.
Most patients present with advanced disease that is often
incurable. This lends itself to therapeutic nihilism that has
been identified among clinicians.18,19 Distance from oncol-
ogy services and total care in the public health sector have
also been associated with lack of treatment.9,11,12
Many studies have shown various factors to be pre-
dictive of no treatment in lung cancer; however, the actual
reasons for no treatment have been poorly documented.
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The aim of this study was to identify specific reasons for
no treatment of lung cancer patients in a cohort where the
treatment decision was discussed and documented at a
multidisciplinary team meeting. We also wanted to esti-
mate the proportion of reasons that might be classed as
being legitimate and not influenced by clinician or patient
preferences.
PATIENTS AND METHODS
South-West Sydney (SWS) is located in the south-
western outskirts of Sydney, New South Wales (NSW),
Australia. It covers an area of 6237 km2 and services a
population of 840,000. The Liverpool and Macarthur Cancer
Therapy Centres provide radiotherapy and chemotherapy ser-
vices across two campuses for this population. These centers
are linked by common staff and treatment protocols. Liver-
pool Hospital is a tertiary care hospital that provides the only
cardiothoracic surgery services for the region. There is an
area cancer registry for SWS, which receives mandatory
notifications of all cancers diagnosed in the region. All
patients seen at the Cancer Therapy Centres also have stag-
ing, pathology, and treatment recorded.
A weekly videoconferenced Lung Cancer Multidis-
ciplinary Meeting (MDM) is held between Liverpool and
Macarthur Cancer Therapy Centres. Presentation of all
newly diagnosed lung cancer patients at the MDM is
encouraged but is at the discretion of individual clinicians.
Prospective data collection on all presented patients has
occurred since December 1, 2005. The data collected
includes patient demographics, comorbidities, perfor-
mance status, histology, diagnostic investigations, stage,
and prior therapy. The MDM consensus is recorded at the
end of the meeting. An assessment is completed 6 months
after the MDM discussion to determine the treatment
actually received.
All patients with newly diagnosed lung cancer who
were presented at the MDM between December 1, 2005,
and December 31, 2007, were reviewed. For patients in
whom the MDM recommended no active anticancer treat-
ment, a reason had been recorded in the database. For
those additional patients who actually received no treat-
ment despite an MDM recommendation for treatment, the
medical records were reviewed to ascertain the reasons.
International evidence-based guidelines from the
UK, USA, and Australia20–25 were reviewed to assign an
optimal treatment for each patient based on pathology,
stage, and performance status (Table 1). The guidelines
were not used to ascertain specific prescriptive treatments
but rather the range of possible treatments supported by
evidence for a particular pathology and stage of disease
and performance status of the patient. Except for Eastern
Cooperative Oncology Group (ECOG) 0 to 3 patients with
limited-stage small cell lung cancer (SCLC), all other
categories of patients had more than one treatment option
available, which would have counted as guideline-based
treatment.
Those patients in whom no anticancer therapy was
recommended by guidelines were compared with those
patients in whom the MDM recommended no treatment
and with those patients who actually received no treatment.
Analysis was performed using SPSS version 17.26 This
study was approved by the local human research ethics
committee.
RESULTS
Between December 1, 2005, and December 31, 2007,
571 SWS residents were diagnosed with primary lung cancer
and 481 new lung cancer patients were seen at Liverpool and
Macarthur Cancer Therapy Centres. During this period, 335
patients with newly diagnosed lung cancer were discussed at
the lung MDM, 149 in 2006 and 186 in 2007. This repre-
sented 70% of all new lung cancer patients seen at the Cancer
Therapy Centres and 59% of the lung cancer population in
SWS. The patient and tumor characteristics are shown in
Table 2.
The patients had a median age of 69 years and
approximately two-thirds were men. Equal proportions
were born in Australia and overseas although the majority
spoke English. Sixty-four percent were of good perfor-
mance status (ECOG 0–1). A total of 82% of patients had
non-small cell lung cancer (NSCLC), 14% SCLC, and 4%
did not have pathologic confirmation of diagnosis. The
majority of patients presented (84%) had locally advanced
or metastatic disease.
There were some differences between patients pre-
sented at the MDM and those seen at the Cancer Therapy
Centres (CTC) and those diagnosed with lung cancer in
SWS. The MDM population had a greater proportion of
men and a smaller proportion of patients aged 80 years and
older. ECOG performance status was difficult to compare
because it was either not recorded (CTC) or missing
(SWS) in a large proportion of patients. The pathology
distribution between MDM and CTC patients was similar.
SWS patients had a greater proportion of patients without
TABLE 1. Guideline Recommended Treatment Based on
Stage and Performance Status20–25
NSCLC ECOG PS 0–2 ECOG PS 3–4
Stage I Surgery or curative radiotherapy Palliative radiotherapy
to symptomatic sitesStage II Surgery  adjuvant chemotherapy
or curative radiotherapy 
chemotherapy
Stage IIIA Surgery  adjuvant/neoadjuvant
chemotherapy  radiotherapy OR
Curative radiotherapy  chemotherapy
Stage IIIB Radiotherapy  chemotherapy,
curative or palliative
Stage IV Palliative chemotherapy  palliative
radiotherapy to symptomatic sites
SCLC ECOG PS 0–3 ECOG PS 4
Limited Curative chemotherapy  radiotherapy Palliative radiotherapy
to symptomatic sitesExtensive Palliative chemotherapy  palliative
radiotherapy to symptomatic sites
ECOG PS, Eastern Cooperative Oncology Group performance status; NSCLC,
non-small cell lung cancer; SCLC, small cell lung cancer.
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pathology, i.e., clinical diagnosis only. It was difficult to
compare the stage of cancer when this was not documented
in 24% of SWS patients. However, if we compare patients
in whom the stage was documented, MDM patients had a
greater proportion of patients with stage III NSCLC and
extensive-stage SCLC and a smaller proportion of patients
with stage IV NSCLC compared with both the CTC and
SWS populations.
Based on evidence-based guidelines, no treatment
was recommended in 13 of the 335 patients (4%) discussed
at the MDM. The MDM recommended no treatment in 32
patients (10%). However, 66 patients (20%) actually re-
ceived no treatment in the 6 months after presentation at
the MDM. Table 3 outlines the reasons for no treatment.
The most common reason for guidelines not recom-
mending any treatment was poor performance status
(85%). The MDM recommended no treatment in a further
19 patients for whom guidelines would have recommended
treatment. The main reasons for this were specific comor-
bidity (47%) or physician decision (32%). The coding of
TABLE 2. Comparison of Patient and Tumour Characteristics Between MDM Population,
Patients Seen at the Cancer Therapy Centres, and All Lung Cancer Patients Diagnosed in
South-West Sydney
MDM (n  335)
Cancer Therapy
Centres (n  481)
South-West
Sydney (n  571) p
Gender
Male 218 (65) 300 (62) 350 (61) 0.0001
Female 117 (35) 181 (38) 221 (39)
Country of birth
Australia 163 (49) 232 (48) 286 (50) NS
Overseas 165 (49) 228 (48) 281 (49)
Unknown 7 (2) 21 (4) 4 (1)
Language
English 275 (82) 396 (82) 293 (51) 0.0001
Other 59 (18) 80 (17) 86 (15)
Unknown 1 (0) 5 (1) 192 (34)
Age (yr)
50 22 (7) 30 (6) 28 (5) 0.001
50–59 47 (14) 71 (15) 85 (14)
60–69 110 (33) 130 (27) 159 (27)
70–79 116 (35) 171 (36) 206 (36)
80 40 (12) 79 (16) 93 (16)
ECOG PS
0–1 213 (64) — 199 (35) 0.0001
2 76 (23) — 57 (10)
3–4 45 (13) — 53 (9)
Unknown 1 (0) — 262 (46)
Pathology
NSCLC 274 (82) 391 (81) 440 (77) 0.0001
Squamous cell 60 (18) 82 (17) 89 (16)
Adenocarcinoma 90 (27) 121 (25) 179 (31)
Large cell carcinoma 109 (32) 140 (29) 122 (21)
NSCLC NOS 15 (5) 48 (11) 50 (9)
SCLC 46 (14) 78 (16) 84 (15)
No pathology 15 (4) 12 (3) 47 (8)
Stagea
NSCLC stage I 29 (9) 23 (5) 48 (8) 0.0001
NSCLC stage II 25 (7) 30 (6) 30 (5)
NSCLC stage III 122 (36) 156 (32) 116 (20)
NSCLC stage IV 113 (34) 194 (40) 176 (31)
NSCLC unknown stage 0 (0) 0 117 (21)
SCLC limited stage 19 (6) 27 (6) 47 (8)
SCLC extensive stage 27 (8) 51 (11) 20 (4)
SCLC unknown stage 0 (0) 0 (0) 17 (3)
Values are given as n (%).
MDM, multidisciplinary meeting; ECOG PS, Eastern Cooperative Oncology Group performance status; NSCLC, non-small cell lung
cancer; SCLC, small cell lung cancer.
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physician decision was made in those cases where no other
reason was stated for no treatment. This was a collective
decision made by the members of the MDM after taking
the patient’s individual factors into consideration. In three
patients (16%), technical factors were the reason behind
lack of treatment. These were factors that precluded safe
delivery of radiotherapy based on the size or location of
the cancer or based on overlap with previous radiotherapy
treatment fields.
A further 34 patients received no treatment despite
an MDM recommendation for treatment. Patient prefer-
ence played a major role in this being the reason in 50% of
cases. Declining performance status, usually as a result of
progressive tumor, accounted for 41%.
In univariate analysis, patient age, performance sta-
tus, presence of comorbidity, language spoken, and tumor
pathology were significantly associated with the lack of
treatment. Older patients were significantly more likely to
have no treatment (p  0.001) (Figure 1). Guidelines
recommended no treatment only in patients aged 70 years
and older, and the MDM recommended no treatment only
in patients aged 60 years and older. However, actual no
treatment was seen across all age groups. More than a
quarter of patients aged 70 years and above and one-third
of those aged 80 years and above received no treatment.
Poorer performance status was significantly associ-
ated with no treatment (p  0.001). Guidelines recom-
mended no treatment only in patients who were ECOG 3 or
4. However, MDM recommendations and actual no treat-
ment spanned all scores of performance status scores
(Figure 2).
Patients who had at least one comorbidity were more
likely to have no treatment (24%) than those who did not
have any (12%) (p  0.005). Patients who did not speak
English were more likely to have no treatment (30%)
compared with those who spoke English (18%) (p  0.02).
Other patient factors such as gender, marital status, and
country of birth were not associated with no treatment. The
patients’ postcode of residence was used to code for
socioeconomic status and accessibility to health services.
Neither of these were significantly associated with no
treatment.
Tumor pathology was predictive of no treatment.
Twenty-two percent of patients with NSCLC had no treat-
ment compared with 9% of patients with SCLC (p  0.03).
There was some variation in no treatment by stage al-
though this was not statistically significant (Figure 3).
Guideline recommended no treatment rates were similar
FIGURE 1. No treatment by age group. Numbers above
bars refer to number of patients in each group.
FIGURE 2. No treatment by Eastern Cooperative Oncology
Group (ECOG) performance status. Numbers above bars re-
fer to number of patients in each group.
FIGURE 3. No treatment by stage of NSCLC and SCLC.
Numbers above bars refer to number of patients in each
group. NSCLC, non-small cell lung cancer; SCLC, small cell
lung cancer; St, stage; Lim, limited stage; Ext, extensive
stage.
TABLE 3. Reasons for No Treatment (n)
No Treatment Guideline MDM Actual Total
Objective reasons
Poor or declining ECOG
PS/progressive disease
11 0 14 25
Comorbidity 0 9 2 11
Technical factors 0 3 0 3
Palliative and asymptomatic 2 0 0 2
Subjective reasons
Physician decision 0 6 1 7
Patient decision 0 1 17 18
Total 13 19 34 66
ECOG PS, Eastern Cooperative Oncology Group performance status; MDM,
multidisciplinary meeting.
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for all stages of NSCLC ranging from 3 to 7%. Guidelines
did not stipulate recommendations for no treatment in any
patients with SCLC. The MDM recommendation for no
treatment fell with increasing stage of NSCLC. However,
the proportion who actually received no treatment was
highest for stage IV and I NSCLC.
In multivariate analysis, patient age, language,
ECOG performance status, and pathology independently
predicted for no treatment (Table 4). Patients who did not
speak English were twice as likely to have no treatment,
whereas patients with poor performance status (ECOG
3–4) were 6 times as likely not to have treatment. Com-
pared with patients younger than 50 years, the likelihood
of receiving no treatment was threefold greater in patients
aged 50 to 69 years and five times greater for those aged 70
years and older. Patients with NSCLC were 2.7 times more
likely to receive no treatment than those with SCLC.
To estimate the best treatment utilization rate that
could potentially be achieved in our MDM cohort, we
looked at the proportion of patients who had an objective
reason for no treatment. Patients in whom the decision for
no treatment was made on the basis of physician or patient
preference were excluded due to potential biases (Table 3).
Based on this, the no treatment rate would be 41 of 335 or
12%. Thus, the best treatment utilization rate that could
potentially be achieved in our MDM cohort would be 88%.
DISCUSSION
The majority of lung cancer patients present with
locally advanced or metastatic disease.7,9,11,12 The com-
plexity of management is underpinned by the multiple
health care disciplines involved, the older age, and coex-
isting comorbidities of this patient population. This has
resulted in up to half of this population not receiving any
treatment for their lung cancer.11,12
Guidelines recommend discussion of lung cancer
patients in a multidisciplinary setting.21,22,25 This has been
shown to improve treatment utilization in lung cancer.12
However, the recommendations will differ depending on
the profile of patients presented at this forum. When
compared with the general lung cancer in SWS, at our
MDM, there was an overrepresentation of patients with
stage III NSCLC and extensive-stage SCLC and corre-
spondingly fewer patients with stage IV NSCLC. In this
group, 12% of patients had an objective reason for not
receiving any treatment (Table 3).
Population-based studies give an indication of what
proportion of patients actually received no anticancer
treatment. In our cohort, the actual no treatment rate was
lower than that described in other population-based studies
in Australia (Figure 4).7,8,10,27 This may be due to the
selection bias associated with MDM presentation and it is
the main limitation of this study. Patients who were not
presented may not have been fit for treatment. This could
explain why the no treatment rates in the general popula-
tion are higher than those seen in our MDM population.
The patterns of care study performed in NSW had
sufficiently detailed demographic and tumor information
to permit comparisons between the MDM population and
the NSW lung cancer population (Table 5).7 SWS is just
one region in the state of NSW that has a population of 6
million. Age and gender distribution were similar. How-
ever, there were significant differences in ECOG perfor-
mance status, pathology, and stage. NSW patients were
more likely to have poorer or unknown ECOG status
compared with the MDM patients. More NSW patients had
no pathologic confirmation of their cancer (13% NSW
versus 4% MDM). NSW contained more patients with
stage I and II NSCLC (25% versus 16%) and correspond-
ingly fewer with stage III NSCLC (19% versus 36%).
Treatment utilization in the MDM cohort could po-
tentially be increased (better performance status patients)
TABLE 4. Multivariate Analysis for Factors Predicting for No
Treatment
n Odds Ratio 95% CI p
Language
English 275 1 0.02
Other 59 2.3 1.2–4.7
Age (yr)
50 22 1 0.01
50–69 157 2.9 0.4–23.8
70 155 5.2 0.7–41.8
ECOG PS
0–1 213 1 0.001
2 76 2 1–4
3–4 45 6.4 3–13.7
Pathology
SCLC 46 1 0.05
NSCLC 288 2.7 0.9–8
ECOG PS, Eastern Cooperative Oncology Group performance status; NSCLC,
non-small cell lung cancer; SCLC, small cell lung cancer; CI, confidence interval.
FIGURE 4. No treatment recommended by multidisci-
plinary team meeting (MDM) compared with actual no
treatment in lung cancer populations. Numbers above
bars: number of patients who received no treatment/total
population. The “MDM” bars refer to no treatment rates
in lung cancer patients discussed at multidisciplinary
meetings in South-Western Sydney (SWS), St. Vincent’s
Hospital, Australia (SVH),28 and Nice, France.29 The “Ac-
tual” bars refer to no treatment rates in lung cancer pa-
tients identified from population data in South-Western
Sydney (SWS),27 Victoria (Vic),8 South Australia (SA),10
and New South Wales (NSW)7 in Australia.
Journal of Thoracic Oncology • Volume 5, Number 7, July 2010 No Anticancer Treatment for Lung Cancer Patients
Copyright © 2010 by the International Association for the Study of Lung Cancer 1029
or decreased (fewer patients with stage I and II NSCLC) by
these factors. Twenty percent of MDM patients received
no treatment compared with 33% of NSW patients (p 
0.0001). This large difference is unlikely to be fully
explained by the differences in population characteristics
alone.
There have been two other studies reporting on the
outcomes of lung cancer MDMs.28,29 Conron et al. reported
on outcomes of an MDM in Victoria, Australia. Two
hundred fifty-seven lung cancer patients presented and
50% of those with NSCLC had stage I and II cancers.28 No
treatment was recommended in 13% of their patients
similar to the 10% in this study, despite the differences in
stage profiles (Figure 4). The reasons for recommendation
of best supportive care were not stated nor the proportion
of patients actually not receiving treatment.
In France, multidisciplinary care for cancer patients
is mandated by law. The profile of the MDM described by
Leo et al.29 is similar to this study, with 74% of the 344
patients presented having stage III or IV cancers. Best
supportive care was recommended in only 4% of patients,
half that of this study (Figure 4). They assessed whether
patients received the recommended treatment. In 15 pa-
tients (4.4%), there was discordance. This was primarily
due to patient preferences (7 of 15) or medical contrain-
dications (5 of 15). The proportion of patients recom-
mended for no treatment by MDMs is affected by the
selection biases of the particular MDM population in
addition to individual patient factors such as performance
status and comorbidities.
The best treatment utilization rate that could poten-
tially be achieved based on indications for treatment and
medical fitness of the patients for treatment was 88%.
There are models of optimal utilization in radiotherapy and
chemotherapy for lung cancer.30,31 However, these models
are based on broad grouping strategies of stage and per-
formance status, and individual patient factors such as
comorbidities cannot be taken into account. For this rea-
son, it is difficult to find a benchmark for what the ideal
treatment utilization should be in lung cancer.
In those population-based studies showing low utili-
zation of treatment for lung cancer (50%), the patients
performance status was not recorded.11,12 In Scotland
where the treatment utilization rate is 62%, a significant
proportion of patients were ECOG 3 or 4 (24%) or had
unknown ECOG status.9 It may be that the general poor
health of the lung cancer population in some countries may
preclude active treatment. However, these are all Western
Countries with well-developed health systems. The popu-
lations would not be dissimilar to that of North America,
which has greater utilization of treatment for lung cancer.
Differences in health care systems may also impact
on treatment utilization. In centralized health care systems
such as in Scotland, UK, and Australia, financial con-
straints in health care expenditure could potentially impact
on treatment utilization in a cancer with poor prognosis.
Conversely, health provider remuneration for treatment in
USA could explain higher utilization of treatment there.
Differing clinician perceptions about the value of treat-
ment in lung cancer may also be a factor.19,32,33 Whatever
the reason, treatment utilization rates of 50 to 60% are low
and are denying treatment for lung cancer patients, which
could be curative or improve their quality of life.
In this cohort, age, performance status, language, and
pathology were found to be associated with no treatment.
Other studies have also shown increasing age and declining
performance status to be predictive of no treatment.9,11,12,27
Patients with poorer ECOG status are physiologically not
able to tolerate treatment and more likely to have treatment-
related complications.
However, age, is a more contentious issue. Many
clinical trials that form the basis for current guidelines had
an upper age limit for trial entry, and the elderly are poorly
represented. A review of SWOG trials found that although
66% of the general lung cancer population were aged 65
years and older, this age group comprised only 39% of
lung cancer patients enrolled in SWOG trials.34 None of
the guidelines, however, have an age cutoff for treatment







(n  1812) p
Gender
Male 218 (65) 1195 (66) NS
Female 117 (35) 617 (34)
Age (yr)
60 69 (21) 353 (19) NS
60–69 110 (33) 478 (26)
70–79 116 (35) 701 (39)
80 40 (12) 275 (15)
Unknown 0 (0) 5 (0)
ECOG PS
0–1 213 (64) 1023 (57) 0.001
2 76 (23) 313 (17)
3–4 45 (13) 332 (18)
Unknown 1 (0) 144 (7)
Pathology
NSCLC 274 (82) 1290 (71) 0.001
SCLC 46 (14) 278 (15)
No pathology 15 (4) 237 (13)
Stagea
NSCLC stage I 29 (9) 343 (19) 0.0001
NSCLC stage II 25 (7) 102 (6)
NSCLC stage III 122 (36) 339 (19)
NSCLC stage IV 113 (34) 600 (33)
NSCLC unknown stage 0 (0) 143 (8)
SCLC limited stage 19 (6) 83 (5)
SCLC extensive stage 27 (8) 189 (10)
SCLC unknown stage 0 (0) 6 (6)
No treatment 66 (20) 598 (33) 0.0001
Values are given as n (%).
a Patients without pathological diagnosis staged with NSCLC group.
MDM, multidisciplinary meeting; ECOG PS, Eastern Cooperative Oncology Group
performance status; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.
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recommendations.20–25 The British Thoracic Society actu-
ally states that “all patients regardless of age, should be
referred and investigated in the same way unless there are
compelling reasons to the contrary, which should be spec-
ified in the clinical record.”35
Increasing age is associated with greater organ dys-
function and so treatment has to be chosen appropriately.
Elderly patients undergoing lung cancer resection may
suffer more perioperative morbidity, but surgical mortality
is comparable with younger patients.36,37 If patients are
medically unfit for surgery then curative radiotherapy is an
alternative treatment.38 Increasing age of patients with
SCLC has been associated with a lower likelihood of
receiving combined modality treatment, although treat-
ment tolerance and efficacy is not related to age.39,40
Radiotherapy and chemotherapy can be delivered to el-
derly patients with NSCLC with acceptable rates of effi-
cacy and toxicity.41,42 Age alone in the presence of good
performance status and lack of significant comorbidities
should not preclude treatment.
In our cohort, which is derived from a heterogeneous
multiracial resident population, it is interesting to note that
patients who did not speak English had significantly higher
rates of no treatment. This may be due to lack of under-
standing about potential benefits, a lack of information
resources in other languages, and preexisting cultural be-
liefs about Western medicine. This area needs further
study and perhaps specific interventions to ensure quality
of care is equivalent to the English-speaking population.
In this study, the prospective nature of data collection
together with the coding of reasons behind lack of treatment
provides some insight into some of the decision-making
processes in the management of lung cancer, compared with
other similar studies. The MDM is the ideal forum for
decision making in lung cancer because the presence of
different specialists should minimize treatment biases that
might occur with any one specialty or one individual. With
lung cancer survival being so poor, the selection of appropri-
ate patients for treatment must be increased if we are to
improve outcomes.
CONCLUSION
The actual proportion of patients receiving no treat-
ment for their lung cancer was greater than that based on
guidelines and MDM recommendations. MDM no treat-
ment recommendations were mainly due to the presence of
comorbidity, whereas reasons for actual no treatment were
largely due to patient preference and declining perfor-
mance status. Guidelines cannot account for individual
patient factors that determine suitability for treatment.
MDM discussion may reduce the proportion of patients
receiving no treatment and could potentially improve sur-
vival and quality of life for lung cancer patients.
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